Mesko S, et al. - Researchers performed an Institutional Review Board-approved retrospective study to quantify Gleason score (GS) heterogeneity within multiparametric magnetic resonance imaging (MRI)-targeted prostate biopsies. They also investigated the influence on National Comprehensive Cancer Network (NCCN) risk stratification. Intratarget heterogeneity was defined as a difference in GS between 2 cores within a single target in patients with ≥2 positive cores. GS heterogeneity was shown by over half of multiparametric MRI-defined targets. A significant link with heterogeneity was not shown by any of the evaluated factors. In comparison to the alone use of systematic biopsy, risk inflation was noted with the addition of high GS from targeted biopsy.